$4.26 Million is the total value of Revelation Capital Management, LLC's 3 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 66.7% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
OMIC | SINGULAR GENOMICS SYSTEMS INC | $3,540,000 | -34.6% | 1,415,846 | 0.0% | 83.16% | +8.6% | |
New | AKILI INC | $556,000 | – | 245,912 | +100.0% | 13.06% | – | |
NPCE | Sell | NEUROPACE INC | $161,000 | -86.9% | 42,972 | -82.7% | 3.78% | -78.2% |
ACCD | Exit | ACCOLADE INC | $0 | – | -58,050 | -100.0% | -6.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-07
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SINGULAR GENOMICS SYSTEMS INC | 4 | Q3 2022 | 83.2% |
NEUROPACE INC | 4 | Q3 2022 | 17.4% |
23ANDME HOLDING CO | 2 | Q1 2022 | 37.4% |
AKILI INC | 1 | Q3 2022 | 13.1% |
ACCOLADE INC | 1 | Q2 2022 | 6.1% |
SOMALOGIC INC | 1 | Q4 2021 | 4.2% |
NATERA INC | 1 | Q4 2021 | 0.7% |
CVRX INC | 1 | Q4 2021 | 0.4% |
View Revelation Capital Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2022-11-07 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-12 |
13F-HR | 2022-02-14 |
View Revelation Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.